Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity for Women 65 and Older

What this Trial Is About

Researchers are evaluating ways to personalize radiotherapy for women aged 65 and older with early-stage, luminal A breast cancer who have had breast-conserving surgery. The study focuses on using the NovaGray Breast® test, a rapid radiosensitivity assay that measures radiation-induced CD8 T-lymphocyte apoptosis (RILA) along with clinical factors to predict the risk of late toxicities such as breast fibrosis and poor cosmetic outcomes that affect quality of life. The goal is to improve treatment decisions by considering individual radiosensitivity. The study observes different radiotherapy approaches including whole breast hypofractionation, volume reduction techniques like intraoperative radiotherapy (IORT), brachytherapy, and external partial breast irradiation. It also considers omission of radiotherapy in select low-risk cases. The NovaGray Breast® test guides these personalized treatment choices to potentially reduce severe breast fibrosis and other side effects. Participants will be followed for up to five years to monitor acute and late breast fibrosis rates and quality of life using the EORTC QLQ-C30 questionnaire. The study includes regular clinical evaluations and uses the radiosensitivity test results to inform radiotherapy decisions. This prospective evaluation aims to integrate individual radiosensitivity testing into routine clinical practice for better patient outcomes.

Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity